Published in Cancer Weekly, August 16th, 2005
The initiation of the first of two registration-directed phase II/III trials is scheduled for the third quarter of 2005. The first trial will target chronic myeloid leukemia (CML) accelerated phase patients who are resistant to high-dose Gleevec. The single-agent, phase II/III trial will initially be conducted in 6 European cancer centers, and is expected to expand to incorporate cancer centers in the U.S. in Q1, 2006.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.